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Abstract
Background: Oncogenic BRAF mutations have been found in diverse malignancies and activate RAF/MEK/ERK signaling, a
critical pathway of tumorigenesis. We examined the clinical characteristics and outcomes of patients with mutant (mut)
BRAF advanced cancer referred to phase 1 clinic.
Methods:We reviewed the records of 80 consecutive patients withmutBRAF advanced malignancies and 149 with wild-type
(wt) BRAF (matched by tumor type) referred to the Clinical Center for Targeted Therapy and analyzed their outcome.
Results: Of 80 patients with mutBRAF advanced cancer, 56 had melanoma, 10 colorectal, 11 papillary thyroid, 2 ovarian and
1 esophageal cancer. Mutations in codon 600 were found in 77 patients (62, V600E; 13, V600K; 1, V600R; 1, unreported).
Multivariate analysis showed less soft tissue (Odds ratio (OR) = 0.39, 95%CI: 0.20–0.77, P = 0.007), lung (OR= 0.38, 95%CI:
0.19–0.73, p = 0.004) and retroperitoneal metastases (OR = 0.34, 95%CI: 0.13–0.86, p = 0.024) and more brain metastases
(OR= 2.05, 95%CI: 1.02–4.11, P = 0.043) in patients with mutBRAF versus wtBRAF. Comparing to the corresponding wtBRAF,
mutBRAF melanoma patients had insignificant trend to longer median survival from diagnosis (131 vs. 78 months, p = 0.14),
while mutBRAF colorectal cancer patients had an insignificant trend to shorter median survival from diagnosis (48 vs. 53
months, p = 0.22). In melanoma, V600K mutations in comparison to other BRAF mutations were associated with more
frequent brain (75% vs. 36.3%, p = 0.02) and lung metastases (91.6% vs. 47.7%, p = 0.007), and shorter time from diagnosis to
metastasis and to death (19 vs. 53 months, p = 0.046 and 78 vs. 322 months, p = 0.024 respectively). Treatment with RAF/
MEK targeting agents (Hazard ratio (HR) = 0.16, 95%CI: 0.03–0.89, p = 0.037) and any decrease in tumor size after referral
(HR = 0.07, 95%CI: 0.015–0.35, p = 0.001) correlated with longer survival in mutBRAF patients.
Conclusions: BRAF appears to be a druggable mutation that also defines subgroups of patients with phenotypic overlap,
albeit with differences that correlate with histology or site of mutation.
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Introduction
The RAS proteins regulate cell proliferation, survival and
differentiation by activating a number of downstream effectors,
including RAF protein kinase. Once activated, RAF stimulates a
signaling cascade involving the MEK/ERK pathway. BRAF, a
serine-threonine kinase, is one of three RAF protein kinase family
members (ARAF, BRAF and CRAF) [1]. The BRAF proto-
oncogene has recently been the focus of intensive research, as its
mutation constitutively activates RAF/MEK signaling, a major
driver of carcinogenesis in various malignancies, most notably in
melanoma, colon cancer, and papillary thyroid cancer1. The most
common BRAF mutation is a substitution of glutamic acid for
valine in codon 600 (V600E) [2–3].
In recent years, a plethora of promising compounds that target
the RAS/RAF/MEK pathway have entered clinical trials, some of
them demonstrating promising clinical activity, mainly in cancers
with BRAF mutations [4–6]. Consequently, testing for activating
mutations in BRAF is becoming more common, especially if
patients are to be treated with BRAF inhibitors, or other pathway
modulators such as MEK inhibitors.
Oncogenic mutations such as BRAF occur across diverse tumor
types. Herein, we examined clinical features and outcome
associated with the presence of BRAF mutations, with the main
objectives being to outline clinical and prognostic characteristics
associated with the presence of BRAF mutations, whether or not
specific BRAF mutations have a distinct clinical course, as well
predictive impact of targeted treatment.
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Methods
Patients
Starting in January 2006, we investigated the BRAF mutation
status of patients with advanced tumors and available tissue
referred to the Clinical Center for Targeted Therapy in the
Department of Investigational Cancer Therapeutics (Phase I
Clinical Trials Program) at The University of Texas MD
Anderson Cancer Center. The registration of patients in the
database, pathology assessment, and mutation analysis were
performed at MD Anderson. In total, 80 consecutive patients
with BRAF mutations were selected.
To define distinguishing features of mutant (mut) BRAF
advanced cancers, we selected a control group of consecutive
patients with wild-type (wt) BRAF advanced cancers seen at our
center during the same time period and matched in a 1:2 ratio by
tumor type with mutBRAF patients.
The MD Anderson Cancer Center Institutional Review Board
has approved the study. Written consent was given by the patients
for their information to be stored in the hospital database and used
for research.
Tissue samples and mutational analysis
Archival formalin-fixed, paraffin-embedded tissue blocks or
material from fine-needle aspiration biopsy obtained from
diagnostic and/or therapeutic procedures were used to test for
BRAF mutations. All pathology was centrally confirmed at MD
Anderson. BRAF mutation testing was performed in a Clinical
Laboratory Improvement Amendment–certified Molecular Diag-
nostic Laboratory within the Division of Pathology and Labora-
tory Medicine at MD Anderson. DNA was extracted from micro-
dissected paraffin-embedded tumor sections and analyzed using a
polymerase chain reaction (PCR)-based DNA sequencing method
for BRAF codons 595–600 mutations of exon 15 by pyrosequenc-
ing as previously described [7]. Substitution of glutamic acid for
valine in codon 600 is denoted as V600E; V600K denotes
substitution of lysine for valine; V600R, arginine for valine.
Whenever possible, we tested for other mutations such as EGFR
(exons 18 and 21) [8], KIT (exons 11, 13 and 17) [9], PIK3CA
(exons 9 and 20) [10], NRAS and KRAS (exon 2) [7,11]. PTEN loss
was assessed using immunohistochemistry (monoclonal mouse
anti-human PTEN, clone 6H2.1, DakoH, Denmark) [12].
Clinical characteristics and treatment evaluation
All clinical variables were assessed by review of the electronic
medical record. Treatment efficacy was evaluated from computed
tomography (CT) scans and/or magnetic resonance imaging
(MRI) at baseline before treatment initiation and then about every
6 to 8 weeks. All radiographs were read in the Department of
Radiology at MD Anderson and reviewed in the Department of
Investigational Cancer Therapeutics tumor measurement clinic.
Prognostic assessment was done using the Royal Marsden
Hospital (RMH) [13] prognostic score as follows: 0 points, normal
lactate dehydrogenase (LDH), albumin $3.5 g/dL, a #2
metastatic sites; 1 point- LDH.upper limit of normal, albumin
,3.5 g/dL, .2 metastatic sites. Patients with 0–1 points had a
good RMH score, and patients with 2–3 points had a poor RMH
score.
Statistical Analysis
Statistical analysis was verified by our statistician (SW). The
following covariates pertaining to patient characteristics were
analyzed: type of cancer, age, gender, race, personal history of
cancer, history of smoking or alcoholism, family history of cancer,
site and number of metastases, presence of ascites, pleural effusion
or deep venous thrombosis, tumor markers (CEA, CA 19-9,
CA125, CA27.29), lactate dehydrogenase, albumin, hemoglobin,
white blood cell count, platelet count, calcium level, site of
mutation, presence of other aberrations (PIK3CA, NRAS or KRAS,
KIT mutation and PTEN loss), date of diagnosis, locally advanced
disease, distant metastases, referral, death or date of last follow-up,
information about best standard systemic treatment for metastatic
disease and treatment with phase 1 trial.
Descriptive statistics were used to summarize patient charac-
teristics. The Fisher exact test was used to test for any association
between two categorical variables. Mann-Whitney U test was used
to test for association between age and BRAF mutation status.
Overall survival (OS) was measured (method of Kaplan-Meier)
from the time of diagnosis, date of metastases, or date of referral to
the date of death or last follow-up, whichever occurred first.
Patients alive were censored at the last follow-up date. Progression-
free survival (PFS) was defined as the time interval between the
start of therapy to the first observation of disease progression (as
determined by Response Evaluation Criteria in Solid Tumors
(RECIST) [36] or death, whichever came first. Patients alive and
without disease progression were censored at the last follow-up
date. Disease-free survival was measured from time of diagnosis to
first distant metastases. Log-rank test was used to compare OS or
PFS among subgroups. Multivariate analysis with the Cox
proportional hazards regression model was used to assess an
independent association between a characteristics and PFS or OS.
The ‘‘enter’’ method was used where all the variables are entered
in the model without checking. Binary logistic regression method
was used to test for any independent correlation between a
categorical variable and BRAF mutational status. The ‘‘enter’’
method was used where all the variables are entered in the model
without checking. All tests were two-sided. A p value less than 0.05
was considered statistically significant. Statistical analysis was
performed using SPSS (version 17.0; SPSS, Chicago, IL, USA).
Results
Patient characteristics
A total of 80 patients with advanced tumors and mutBRAF were
identified. The median age was 52 years (range, 18–78 years), and
43 were men (54%). The majority of patients had melanoma
(n= 56, 70%) followed by papillary thyroid carcinoma (n= 11,
14%), colorectal cancer (n = 10, 13%), and other tumor types
(ovarian cancer, n = 2, 2%; esophageal cancer, n = 1, 1%)
(reflecting referral patterns to our clinic), (Table 1).
The most common metastatic sites were lungs (n = 48, 60%),
superficial lymph nodes (n = 39, 49%), peritoneum (n= 33, 41%),
liver (n = 31, 39%), brain (n = 27, 34%), soft tissue (n = 26, 33%),
bones (n = 20, 25%) and retroperitoneal lymph nodes (n = 9, 11%).
We identified 149 control patients with advanced cancers who
tested negative for BRAF mutations in the same time period and
who were matched on a 1:2 basis by tumor type with mutBRAF
patients. For papillary thyroid cancer, matching was done with a
1:1 ratio due to an inadequate number of patients referred who
had tests done and tested negative for BRAF mutation. The
detailed patient characteristics are shown in Table 1.
Groups with mutBRAF and wtBRAF were similar in terms of
median time from diagnosis to referral to the phase 1 clinic as
calculated by log-rank method (12 vs. 12.7 months, p = 0.95).
Initial cancer staging at diagnosis was also equally distributed
among the two groups. Patients were treated on a clinical trial if
they had failed to respond to conventional treatment. Whenever
possible, patients with mutBRAF were offered treatment targeting
BRAF Mutations in Advanced Malignancies
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Table 1. Clinical characteristic of 80 patients with BRAF-mutant disease and 149 matched controls with BRAF-wild-type (Univariate
Analysis).
mutBRAF (N=80) wtBRAF (N=149) P value
Age at diagnosis (median, range) 52 (18–78) 58 (24–87) 0.002
Age at diagnosis $60 years 27 (34%) 69 (46%) 0.07
Gender
Men 43 (54%) 100 (67%) 0.06
Women 37 (46%) 49 (33%) 0.06
Race
Caucasian 67 (87%) 130 (87%) Not significant
Hispanic 8 (10%) 9 (6%) Not significant
Asian 2 (3%) 1 (1%) Not significant
African-American 0 (0%) 9 (6%) Not significant
Type of Cancer
Melanoma 56 (70%) 112 (75%) Not significant
Colorectal cancer 10 (13%) 20 (14%) Not significant
Papillary thyroid cancer 11 (14%) 11 (7%) Not significant
Ovarian cancer 2 (2%) 4 (3%) Not significant
Esophageal cancer 1 (1%) 2 (1%) Not significant
Personal history of cancer 15 (19%) 27 (18%) 0.99
Family history of cancer 62 (78%) 120 (81%) 0.61
First degree 48 (60%) 96 (64%) 0.56
Age,60 years 25 (31%) 43 (29%) 0.76
First degree & age,60 16 (20%) 30 (20%) 0.99
Social history
Tobacco 26 (33%) 61 (41%) 0.25
Alcohol 11 (14%) 28 (19%) 0.36
Site of metastasis
Brain 27 (34%) 45 (30%) 0.65
Liver 31 (39%) 67 (45%) 0.40
Lung 48 (60%) 118 (79%) 0.003
Retroperitoneum 9 (11%) 37 (25%) 0.004
Bone 20 (25%) 41 (28%) 0.75
Superficial Lymph Node 39 (49%) 76 (51%) 0.78
Soft tissue 26 (33%) 75 (50%) 0.01
Peritoneum 33 (41%) 61 (41%) 0.99
Mediastinum 19 (24%) 38 (26%) 0.87
Stage at diagnosis
Early stage 57 (71%) 91 (61%) 0.14
Locally advanced stage 13 (16%) 36 (24%) 0.18
Metastatic stage 10 (13%) 22 (15%) 0.69
Pleural effusion 11 (14%) 17 (11%) 0.60
Ascites 8 (10%) 13 (9%) 0.74
Thrombosis 15 (19%) 30 (20%) 0.80
Site of mutation
C600/599 1 (V600E/T599S) N/A N/A
C600 77 ( 62 V600E, 13 V600K,
1 V600R, 1 unknown)
N/A N/A
C601 2 (2 K601E) N/A N/A
PTEN loss 2/71 (29%) 2/20 (10%) 0.27
KRAS mutation 0/24 (0%) 13/45 (29%) 0.002
PIK3CA mutation 1/26 (4%) 4/46 (9%) 0.64
BRAF Mutations in Advanced Malignancies
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the RAF/MEK pathway. Patients had a median of two prior
treatments, regardless of BRAF status.
Types of BRAF mutations
Of the 80 patients with mutBRAF, 77 (96%) had mutations in
codon 600 and two (3%) in codon 601. One (1%) patient had
simultaneous mutations in codons 599 and 600. Of the 77 patients
with codon 600 mutBRAF, 62 (81%) had V600E mutations
(melanoma, n= 40; colorectal, n = 8; papillary thyroid cancer,
n = 11; esophageal, n = 1 and ovarian, n= 2), 13 (17%) V600K
mutations (melanoma, n= 12; colorectal cancer, n = 1), 1 (1%)
V600R mutation (melanoma, n = 1) and one of unreported type
(colorectal, n = 1) (Table 1).
BRAF mutations and clinical features
Univariate Analysis. Patient age at diagnosis was
significantly younger for patients with mutBRAF (median age = 52
years) versus wtBRAF disease (median age = 58 years) (p = 0.002).
Men were more commonly represented in both mutBRAF and
wtBRAF groups, but the proportion of women trended towards
being greater in the mutBRAF group (46% vs. 33%, p= 0.06).
There were no significant differences between the mutBRAF and
wtBRAF group for other characteristics, including ethnicity,
personal, social and family history, complications including
thrombosis, ascites and pleural effusion (Table 1).
Patients who had mutBRAF tumors had less frequent involve-
ment of the lungs (60% vs. 79%; p= 0.003), retroperitoneal nodes
(11% vs. 25%; p= 0.004), and soft tissue (33% vs. 50%; p= 0.01).
In subgroup analysis, this pattern was also observed in each of the
three major tumor types; however due to the small number of
patients in the non-melanoma cohort, significance was only
achieved for patients with melanoma (unshown data). There was
no difference in involvement of other sites by metastases.
Multivariate Analysis. In multivariate analysis using a
logistic regression model, patients with mutBRAF had less
frequent metastases to (i) soft tissue (OR=0.39, 95% CI: 0.20–
0.77, p = 0.007); (ii) lung (OR=0.38, 95% CI: 0.19–0.73,
p = 0.004); and (ii) the retroperitoneum (OR=0.34, 95% CI:
0.13–0.86, p= 0.024) (Table 2). Women were more likely to have
mutBRAF than wtBRAF (OR=1.92, 95% CI: 1.02–3.57, p = 0.045).
Patients with mutBRAF compared with wtBRAF were more likely to
have brain metastases (OR=2.05, 95% CI: 1.02–4.11, p = 0.043).
Patients younger than 60 years showed a trend towards higher
likelihood of BRAF mutations (OR=1.88, 95% CI: 0.99–3.70,
p = 0.053). In subgroup analysis of melanoma, this trend was
statistically significant (multivariate p value = 0.023) (Table 3). The
smaller numbers of patients with other cancers precluded a
separate analysis for this factor. An interval from diagnosis to
distant metastases of $2 years was more likely to be associated
with mutBRAF (Odds ratio (OR)= 2.84, 95% Confidence interval
(CI): 1.18–4.14, p = 0.013) (Table 2). However, in disease specific
analyses, in colorectal and papillary thyroid cancer, the proportion
of patients with a disease-free interval from diagnosis to metastases
of over two years was less for patients with mutBRAF disease, but
this did not reach statistical significance because of the small
number of patients in each subgroup (data not shown).
Co-Existing Mutations/Molecular Aberrations
A subset of mutBRAF patients with available data also had PTEN
loss (2/7; 29%) or PIK3CA mutations (1/26; 4%) (Table 1). In
patients with wtBRAF, 2/20 (10%) had PTEN loss and 4/46 (9%)
had PIK3CA mutation. There was no difference in the rates of
PTEN loss or PIK3CA mutations between mutBRAF vs. wtBRAF
groups, but the small numbers of patients may preclude firm
conclusions, especially in the PTEN group.
As expected KRAS and NRAS mutations were significantly less
common in the mutBRAF group compared to the wtBRAF group
(KRAS: 0/24 (0%) vs. 13/45 (29%), p = 0.002; NRAS: 1/17 (6%) vs.
42/108 (39%), p = 0.006). Of interest, it should be noted that one
patient had a concomitant BRAF and NRAS mutation.
BRAF status and Progression-free survival (PFS) on
conventional standard treatment
We analyzed PFS on conventional treatment (before referral to
phase 1 clinic) for metastatic disease according to BRAF status. We
chose the longest PFS each patient had ever achieved on a
conventional treatment.
When analyzed with all patients included, there was no overall
difference in median PFS between mutBRAF vs. wtBRAF disease
(7.0 months, 95%CI 5.6–8.3 vs. 7.1 months, 95%CI 5.7–8.5;
p = 0.49). However, patients with colorectal cancer and mutBRAF
had a median PFS of 7 months (95%CI 5.3–8.6) compared to 9.2
months (95%CI 7.4–10.9) in wtBRAF (p = 0.002) (Figure 1). In
multivariate analysis, mutBRAF was an independent prognostic
factor for shorter PFS (HR: 3.76, 95% CI 1.22–11.49, p = 0.02) on
the best standard systemic therapy in metastatic colorectal cancer.
In melanoma and papillary thyroid cancer, there was no
difference in median PFS in patients with mutBRAF compared to
wtBRAF (4.3 months, 95%CI 1.9–6.8 vs. 5.5 months, 95%CI 3.5–
mutBRAF (N=80) wtBRAF (N=149) P value
NRAS mutation 1/17 (6%) 42/108 (39%) 0.006
KIT mutation 0/30 (0%) 3/93 (3%) 0.99
EGFR mutation 0/18 (0%) 0/43 (0%) 0.99
Median time from diagnosis to metastases (months) (95%CI)
Melanoma 44 (17–71) 20 (16–24) 0.058
Colorectal cancer 0 8 (0–28.4) 0.96
Papillary thyroid cancer 37 (0–74.7) 73 (29.8–116.1) 0.45
Combined 28 (12.8–43.1) 19 (14.5–23.5) 0.13
Time from diagnosis to metastasis $2 years 45 (56%) 63 (42%) 0.052
1Denominator refers to the number of patients tested.
doi:10.1371/journal.pone.0025806.t001
Table 1. Cont.
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6.7; p= 0.29; 24 months, 95%CI 14.4–33.5 vs. 25 months, 95%CI
0–55.4; p = 0.65 respectively).
BRAF Status and Survival
Univariate Analysis. We analyzed OS from time of
diagnosis and from time of metastasis. The median OS from
time of diagnosis of mutBRAF patients was 322 months vs. 112
months (95%CI 58.2–165.7) for wtBRAF patients (p = 0.24). The
median OS from time of metastasis of mutBRAF patients compared
to wtBRAF was 99 months (95%CI 17.1–180.8) vs. 51 months
(95%CI 38.7–63.2) (p = 0.58).
In disease specific subgroup analysis, the median OS from
diagnosis and from metastasis was numerically longer in
melanoma patients with mutBRAF compared to wtBRAF (131
months 95%CI 52.7–209.2 vs. 78 months, 95%CI 41.8–114.1;
p = 0.14 and 35 months 95%CI 8.7–61.2 vs. 30 months, 95%CI
8.3–53.6; p= 0.63 respectively). In contrast, in colorectal cancer,
the median OS from diagnosis and from metastasis was
numerically shorter in mutBRAF patients compared to wtBRAF
(48 months 95%CI 23.4–72.5 vs. 53 months, 95%CI 0–125.2;
p = 0.22 and 30 months, 95%CI 14.5–45.4 vs. 53 months, 95%CI
38.8–67.1; p = 0.26 respectively). Small number of patients in
disease specific subgroups precluded more definite conclusions and
might explain the lack of statistical significance. The OS from time
of diagnosis and metastasis did not differ between mutBRAF and
wtBRAF patients with papillary thyroid cancer. The median OS
from time of diagnosis was not reached after a follow-up of 133
and 138 months for mutBRAF and wtBRAF respectively. Also, the
median OS from metastases was not reached with a median
follow-up of 67 and 46 months respectively.
Further, we analyze the prognostic significance of NRAS in
melanoma by stratifying our melanoma patients as follows:
mutBRAF/wtNRAS, wtBRAF/mutNRAS, and wtBRAF/wtNRAS. A
median OS from diagnosis in each of the 3 groups was 131 months
(95%CI 81.6–180.3) (mutBRAF/wtNRAS), 67 months (95%CI 29–
105) (wtBRAF/mutNRAS), and 109 months (95%CI 51.6–166.3)
(wtBRAF/wtNRAS).The OS difference between mutBRAF/wtNRAS
and wtBRAF/mutNRAS was of borderline statistical significance
Table 2. Multivariate analysis by logistic regression model showing the clinico-pathological features correlated with the BRAF
mutation.
Clinical feature Odds Ratio Lower 95% Upper 95% P value
Age,60 years 1.88 0.99 3.70 0.053
Women 1.92 1.02 3.57 0.045
Metastatic site
Soft tissue 0.39 0.20 0.77 0.007
Brain 2.05 1.02 4.11 0.043
Lung 0.38 0.19 0.73 0.004
Liver 0.86 0.46 1.63 0.665
Retroperitoneum 0.34 0.13 0.86 0.024
Bone 1.10 0.53 2.26 0.78
Peritoneum 0.97 0.51 1.83 0.92
Superficial lymph node 0.91 0.47 1.75 0.79
Time from diagnosis to metastasis $2 years 2.21 1.18 4.15 0.013
doi:10.1371/journal.pone.0025806.t002
Table 3. Multivariate analysis by logistic regression model showing the clinico-pathological features correlated with the BRAF
mutation in melanoma patients.
Clinical feature Odds Ratio Lower 95% Upper 95% P value
Age,60 years 2.57 1.13 5.81 0.023
Women 2.27 1.01 5.12 0.047
Metastatic site
Soft tissue 0.36 0.16 0.83 0.017
Brain 2.37 1.05 5.37 0.038
Lung 0.28 0.12 0.63 0.002
Liver 0.93 0.41 2.08 0.85
Retroperitoneum 0.32 0.11 0.95 0.04
Bone 1.39 0.57 3.42 0.46
Peritoneum 0.78 0.34 1.78 0.56
Superficial lymph node 0.74 0.34 1.62 0.45
Time from diagnosis to metastasis $2 years 2.96 1.36 6.45 0.006
doi:10.1371/journal.pone.0025806.t003
BRAF Mutations in Advanced Malignancies
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(p = 0.05). A median OS from time of metastasis was 35 months
(95%CI 8.5–61.5), 20 months (95%CI 10.3–29.6), and 51 months
(95%CI 4.8–97.1), respectively (p = 0.45). These data suggest that
patients with mutBRAF melanoma survive longer than those with
NRAS-mutant disease, but that the survival of mutBRAF melanoma
is not different from that of melanoma patients with wtBRAF and
wtNRAS.
Multivariate analysis. A multivariate analysis on all 229
patients based on age, gender, RAS (KRAS, NRAS) mutations,
BRAF mutations, and disease type was conducted to determine
whether any of these factors affects survival. NRAS mutation and
male gender were the only independent factors associated with
shorter OS from time of diagnosis (Hazard ratio (HR): 2.52,
95%CI 1.32–4.80, p = 0.005 and HR: 2.84, 95%CI 1.46–5.53,
p = 0.002, respectively) whereas diagnosis of melanoma predicted
a better OS from time of diagnosis (HR: 0.15, 95%CI 0.04–0.58,
p = 0.005). Male gender was the only factor predicting poor OS
from time of metastasis (HR: 2.79, 95%CI 1.42–5.45, p = 0.003).
A disease-specific multivariate analysis including age, gender,
RAS (KRAS, NRAS) mutations and BRAF mutations was performed.
In melanoma, only NRAS mutation and male gender were
associated with shorter OS from time of diagnosis (HR: 2.16,
95% CI 1.11–4.18, p= 0.02 and HR: 2.64, 95% CI 1.28–5.41,
p = 0.008, respectively). Male gender was the only prognostic
factor for shorter OS from time of metastasis (HR: 2.84, 95% CI
1.35–5.97, p = 0.006). In colorectal cancer, only KRAS mutation
was identified as an independent indicator for poor OS from time
of diagnosis and metastasis (HR: 13.56, 95% CI 1.61–113.88,
p = 0.016 and HR: 5.46, 95% CI 1.07–27.89, p= 0.04 respective-
ly). We also detected a trend for mutBRAF to predict poor OS from
diagnosis or first time of metastasis (HR: 8.31, 95% CI 0.95–72.56,
p = 0.055 and HR: 4.05, 95% CI 0.75–21.76, p = 0.10, respec-
tively).
In multivariate analysis, no prognostic factor was detected for
papillary thyroid carcinoma, perhaps due to the low number of
cases.
Survival in the Clinical Center for Targeted Therapy
(phase I clinic) according to the BRAF status
We performed a univariate and multivariate analysis to examine
the factors that might predict OS from time of referral to the
Clinical Center for Targeted Therapy (Phase I Program) until
death in mutBRAF patients. Factors included were: age ($60 vs.
,60 years, gender (male vs. female), tumor type, RMH prognostic
score, age, Eastern Cooperative Oncology Group (ECOG)
performance status (0–1 vs. $2), treatment with RAF/MEK
targeting agents vs. never treated with RAF/MEK targeting agent,
any decrease in target lesion size vs. no decrease after referral to
the phase 1 trial.
Univariate analysis in mutBRAF patients. In univariate
analysis, we observed a longer OS from referral in women vs. men
(not reached in both groups, p = 0.015 and HR 2.62, 95%CI
1.14–6.01; p = 0.02), RMH score of 0–1 vs. 2–3 (not reached vs. 5
months, 95%CI 3–7; p,0.001 and HR 3.69, 95%CI 1.74–7.82;
p = 0.001), performance status #1 vs. 2–4 (not reached vs. 6
months, 95%CI 2.1–9.9; p = 0.035 and HR 2.51, 95%CI 1.01–
6.28; p = 0.048), treatment with RAF/MEK targeting agents (56
of the 80 patients received RAF/MEK targeting agents including
37 with melanoma, 10 with papillary thyroid, 8 with colon cancer
and 1 with ovarian cancer) vs. treatment with any other agents or
no treatment (not reached vs. 5 months, 95%CI 3.4–6.6; p,0.001
and HR 0.20, 95%CI 0.095–0.43; p,0.001), papillary thyroid
cancer vs. other cancers (not reached in both groups, p = 0.018
and HR 0.09, 95%CI 0.10–0.89; p = 0.04), and any decrease in
tumor size on any phase I clinical trial vs. no decrease (not reached
vs. 6 months, 95%CI 4.7–7.2; p,0.001 and HR 0.09, 95%CI
0.025–0.32; p,0.001) (Figure 2 and Table 4).
By excluding patients who did not get enrolled into a phase 1
trial after referral (13 patients total), we found that mutBRAF
patients treated with RAF/MEK targeting agents has improved
survival after referral compared to mutBRAF patients treated with
any other agents (not reached vs. 5 months, 95%CI 4–6; p = 0.002
and HR 0.26, 95%CI 0.10–0.66; p= 0.005) (Figure 3).
Figure 1. Kaplan Meier curve showing progression-free survival on best standard systemic treatment comparing patients with
mutBRAF vs. wtBRAF metastatic colorectal cancer. (One patient with inadequate records on prior treatment was excluded).
doi:10.1371/journal.pone.0025806.g001
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Multivariate analysis in mutBRAF patients. In
multivariate analysis, the only two factors that predicted a
superior OS after referral to the Phase I clinic in the mutBRAF
group were treatment with any RAF/MEK targeting agents (HR
0.16, 95% CI, 0.03–0.89, p= 0.037) and any decrease in tumor
size (RECIST measurement) on any phase I trial (HR 0.07, 95%
CI, 0.015–0.35, p= 0.001) (Figure 4). Of note, the HR values of
the following predictive factors ‘‘melanoma vs. non melanoma’’,
‘‘colorectal cancer vs. non colorectal cancer’’ and ‘‘papillary
thyroid cancer vs. non papillary thyroid cancer’’ are extremely
high, compared to their HR calculated by univariate analysis
(figure 4). This discrepancy could be explained by the difference in
methodology used. Despite their high absolute values, this should
be interpreted cautiously provided they don’t have any statistical
significance as demonstrated by a p value close to 1 and a 95%
confidence interval that contains zero. Furthermore, their
extremely wide 95CI% is indicative of the poor estimate of their
value.
Univariate analysis inwtBRAF patients. A similar analysis
was conducted in the wtBRAF group for the 104 patients referred.
Univariate analysis revealed superior OS from referral associated
with the following: RMH score of 0–1 compared to RMH score of
2–3 (50 months, 95%CI 6.4–93.3 vs. 6 months, 95%CI 2–10.3;
p,0.001 and HR 2.94, 95%CI 1.56–5.56; p = 0.001), treatment
with RAF/MEK targeting agents vs. treatment with any other
agents or no treatment (51 months vs. 10 months, 95%CI 7.1–
12.9; p = 0.014 and HR 0.32, 95%CI 0.12–0.83; p= 0.019), no
brain metastases vs. brain metastases detected (15 months, 95%CI
0–34.3 vs. 7 months, 95%CI 3–10.3; p = 0.004 and HR 2.47,
95%CI 1.31–4.65; p = 0.005), non melanoma vs. melanoma (50
months vs. 10 months, 95%CI 6–13.9; p = 0.006 and HR 2.57,
95%CI 1.27–5.18; p= 0.008) and any decrease in tumor size vs.
no decrease (50 months vs. 10 months, 95%CI 6.2–13.8; p= 0.006
and HR 0.32, 95%CI 0.13–0.75; p = 0.009) (Table 5).
By excluding patients who did not get enrolled into a phase 1
trial after referral (18 patients total), we found that wtBRAF
patients treated with RAF/MEK targeting agents has a trend
towards improved survival after referral compared to wtBRAF
patients treated with any other agents (51 months vs. 10 months,
95%CI 4.7–15.9; p = 0.052 and HR 0.39, 95%CI 0.14–1.04;
p = 0.06)
Multivariate analysis in wtBRAF patients. In the
multivariate analysis, none of these factors was significantly
associated with a better OS from referral (Figure 5).
Characteristics of Melanoma Patients with V600K BRAF
mutation
We further investigated the behavior of mutBRAF melanoma
with V600K substitution compared to other subtypes of BRAF
mutation. (There were 13 patients with V600K mutations
including 12 with melanoma and one with colorectal cancer). In
the melanoma group, we compared patients with V600K BRAF
mutations vs. non-V600K BRAF mutations (the vast majority
being V600E). We found that V600K was associated with more
brain (75% vs. 36.3%, p= 0.02) and lung metastases (91.6% vs.
47.7%, p= 0.007). (The single patient with colorectal cancer and
V600K also had brain and lung metastases). V600K melanomas
metastasized earlier (median time to metastasis = 19 months,
95%CI 0–49 vs. 53 months, 95%CI 33–72, p = 0.046), and were
associated with a shorter OS from time of diagnosis (median 78
months, 95%CI 10–146 vs. 322 months, p = 0.024) (Figure 6).
We also compared the OS from diagnosis and from metastases
between V600K melanoma vs. wtBRAF melanoma and it was not
statistically different (P = 0.53 and 0.54, respectively).
Among the 13 patients with V600K BRAF mutation, eight
received RAF/MEK targeting agents (of which one was colorectal
cancer), three did not receive treatment (only best palliative care)
and two received other targeting agents. There were two patients
Figure 2. Kaplan-Meier estimate of overall survival from time of referral to phase 1 clinic in patients with BRAF mutation who
showed any decrease vs. no decrease in size of target lesions on phase 1 trial. (Patients who did not have tumor measurements at the time
of last follow-up (N= 9) or patients who were not enrolled in a phase 1 trial after referral (N = 13) were excluded).
doi:10.1371/journal.pone.0025806.g002
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with stable disease of over four months, but no partial or complete
remissions.
Discussion
BRAF is one of the most frequently mutated protein kinase in
cancer [14]. It has been reported in approximately 40 to 60% of
melanoma, 40 to 70% of papillary thyroid carcinoma and 5 to
15% of colorectal cancer cases [6]. In this study we examined
whether mutBRAF cancers exhibit any distinctive clinical features
compared to wtBRAF cancer.
Overall, we found a higher frequency of women and younger
patients with cancer harboring BRAF mutation compared to those
without the mutation. These results are consistent with those in a
smaller series (18 patients) with mutBRAF melanoma, in whom a
higher frequency of patients younger than 60 and women was noted
[15]. In our study, mutBRAF cancers were less likely to metastasize to
the soft tissue, retroperitoneum and lungs and more likely to
metastasize to the brain, suggesting that mutBRAF might affect the
metastatic spread pattern of the disease. In the subset of patients
with melanoma, the presence of mutBRAF is more likely associated
with a time from diagnosis to distant metastasis beyond 2 years.
Kumar et al also reported a longer disease-free survival in
mutBRAF melanoma compared to those without the mutation,
although the difference was not statistically significant [16]. In a
large Australian series of 207 patients with melanoma, mutBRAF
was also associated with younger age; however, other clinical
features, including time to metastases, response to chemotherapy
and metastatic site were essentially indistinguishable [17]. In
another report of 68 patients with melanoma, 30 of whom had
mutant BRAF, an increase in the incidence of liver metastases was
noticed in the mutBRAF group [18].
In mutBRAF colorectal cancer, Tran et al [19] observed a higher
incidence of peritoneal disease and central nervous system
involvement, but a lower incidence of lung metastases and a
shorter OS from time of diagnosis. These data support our
findings albeit without statistical significance, perhaps due to the
small number of patients with colorectal cancer.
Some differences in the behavior of mutBRAF cancer were seen
across histologies. Whereas mutBRAF vs. wtBRAF is associated with
a trend towards longer OS from time of diagnosis in melanoma,
OS from time of diagnosis tended to be shorter in colorectal
cancer, albeit without reaching significance, perhaps due to the
low number of patients. In multivariate analysis, NRAS and male
gender were the only factors correlated with diminished OS from
time of diagnosis in melanoma. Scoggins et al [20] found male
gender associated with unfavorable survival in melanoma,
however, gender difference did not appear to be a significant
Table 4. Univariate analysis of survival predictors after referral to phase 1 clinic in patients with mutBRAF advanced cancer.
Predictor
Median OS
(95% CI) N P value HR 95%CI P value
Age$60 Unreached 36 0.57 1.23 0.58–2.58 0.58
Age,60 Unreached 44
Male Unreached 43 0.015 2.62 1.14–6.01 0.02
Female Unreached 37
RMH score1 2–3 5 (3–7) 57 ,0.001 3.69 1.74–7.82 0.001
RMH score 0–1 Unreached 23
Performance status .1 6 (2.1–9.9) 11 0.035 2.51 1.01–6.28 0.048
Performance status 0–1 Unreached 69
RAF/MEK targeting agents Unreached 56 ,0.001 0.20 0.095–0.43 ,0.001
Other2 5 (3.4–6.6) 24
Brain metastasis Unreached 27 0.08 1.90 0.89–4.05 0.09
No Brain metastasis Unreached 53
Time from diagnosis to metastases $2 years3 Unreached 45 0.36 0.71 0.33–1.51 0.38
Time from diagnosis to metastases ,2 years Unreached 34
Melanoma Unreached 56 0.38 1.46 0.60–3.57 0.39
Non melanoma Unreached 24
Colorectal cancer 5 (2.1–7.9) 10 0.11 2.13 0.80–5.69 0.12
Non Colorectal cancer Unreached 70
Papillary thyroid cancer Unreached 11 0.018 0.09 0.10–0.89 0.04
Non papillary thyroid cancer Unreached 69
Any decrease tumor size4 Unreached 40 ,0.001 0.09 0.025–0.32 ,0.001
Any increase tumor size 6 (4.7–7.2) 18
1Royal Marsden Hospital (RMH) 13 prognostic score is determined as follows: 0 points, normal lactate dehydrogenase (LDH), albumin $3.5 g/dL, a #2 metastatic sites;
1 point- LDH.upper limit of normal, albumin ,3.5 g/dL,.2 metastatic sites. Patients with 0–1 points had a good RMH score, and patients with 2–3 points had a poor
RMH score.
2Includes patients treated with other agents (N = 11) as well as patients who never started on phase 1 trial (N = 13).
3One patient of whom the exact date of diagnosis was not documented was excluded only from the univariate analysis comparing the OSref between patients who had
a time from diagnosis to metastasis less or more than 2 years.
4Patients who never had a restaging at the last follow-up or who never started on a phase 1 trial were excluded in the univariate analysis (N = 22).
doi:10.1371/journal.pone.0025806.t004
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Figure 3. Kaplan-Meier estimate of overall survival from time of referral to phase 1 clinic in patients withmutBRAF treated with RAF/
MEK targeting agents or other phase 1 trials. Tic marks represent patients still alive at the last follow-up. (Of 80 patients with BRAF mutations,
56 received a RAF/MEK targeting agents, 11 received a non RAF/MEK targeting agents and 13 were not enrolled on a phase 1 trial).
doi:10.1371/journal.pone.0025806.g003
Figure 4. Forest plot summarizing the clinical factors affecting overall survival after referral and displaying their hazard ratio and
95% Confidence interval calculated by Cox proportional hazards regression model in patients with mutBRAF advanced cancer.
doi:10.1371/journal.pone.0025806.g004
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factor in a larger retrospective study [21]. Houben et al [22]
showed a significantly decreased survival of mutBRAF metastatic
melanoma, which is discordant with our data. In our population,
the longer disease-free interval and possibly the introduction of
new targeted therapy against mutBRAF melanoma [6] might
explain, at least in part, the improvement in overall survival from
time of diagnosis favoring the mutBRAF group.
mutBRAF was in general mutually exclusive with the presence of
mutRAS (KRAS, NRAS). Interestingly, however, we observed one
patient with a concomitant NRAS and BRAF mutation. This
observation might be explained by different clones of cancer cells
inside the tumor with distinct dual mutations. A similar finding
was previously reported in familial melanoma, with CDKN2A as
well as BRAF and NRAS mutations [23]. It is believed that BRAF
and NRAS mutations can coexist within the same melanoma but
not at the single-cell level [24].
We also examined the response to best standard systemic
treatment. In melanoma, we noted that there was a trend towards
a shorter PFS among patients with mutBRAF but this did not reach
statistical significance. Findings in the published literature are
conflicting. Joseph et al did not find an impact of NRAS or BRAF
mutational status on response to high dose interleukin-2 in
metastatic melanoma [25]. Similarly, Chang et al [18] reported no
difference in response rate to systemic treatment between mutBRAF
and wtBRAF melanoma. In another series by Kumar and
colleagues, patients with mutBRAF melanoma had a diminished
response to therapy [16]. In colorectal cancer, we showed that
mutBRAF was independently associated with a shorter PFS on best
standard systemic therapy. Our observations are consistent with
those of others which have demonstrated that mutBRAF is an
adverse predictor in colorectal cancer [26–29]. Further, it has
been recently suggested that mutBRAF may also predict resistance
to cetuximab-based regimens, though it is still unclear whether the
mutation is indeed a predictor of resistance or a prognostic marker
for a subgroup that simply does worse [30–32]. mutBRAF has also
been linked to a shorter PFS on standard chemotherapy in few
studies [33], although these findings have been disputed by others
[28]. In regard to thyroid cancer, many series have demonstrated
high-risk features associated with mutBRAF in papillary thyroid
carcinoma. Xing et al [34] also reported an association between
mutBRAF and the rate of tumor recurrence, though these results
have not been confirmed by other studies [35]. The number of
patients with papillary thyroid cancer in our study precluded
making conclusions on this issue.
Our study demonstrated that treatment with RAF/MEK
targeting agents and initial tumor shrinkage are independent
factors associated with improved survival in patient with mutant
BRAF. These findings support data from a series of published
Table 5. Univariate analysis of survival predictors after referral to phase 1 clinic in patients with wtBRAF advanced cancer.
Predictor Median OS (95% CI) N4 P value HR 95% CI P value
Age$60 13.5 (7–20) 46 0.84 0.93 0.49–1.77 0.84
Age,60 11.1 (4.6–17.5) 58
Male 10.3 (6.8–13.7) 69 0.21 1.56 0.76–3.21 0.22
Female Unreached 35
RMH score1 2–3 6.2 (2–10.3) 36 ,0.001 2.94 1.56–5.56 0.001
RMH score 0–1 49.8 (6.4–93.3) 68
Performance status .1 Unreached 31 0.20 0.62 0.29–1.30 0.21
Performance status 0–1 9.5 (3.2–15.7) 73
RAF/MEK targeting agents 50.6 22 0.014 0.32 0.12–0.83 0.019
Other2 10 (7.1–12.9) 82
Brain metastasis 6.7 (3–10.3) 33 0.004 2.47 1.31–4.65 0.005
No Brain metastasis 15.3 (0–34.3) 71
Time from diagnosis to metastases $2 years 15.3 (0–37) 43 0.19 0.65 0.34–1.24 0.19
Time from diagnosis to metastases ,2 years 9.5 (5.5–3.4) 61
Melanoma 10 (6–13.9) 67 0.006 2.57 1.27–5.18 0.008
Non melanoma 49.8 37
Colorectal cancer 8.9 (6.5–1.3) 20 0.74 1.13 0.53–2.40 0.74
Non Colorectal cancer 13.7 (4.9–22.6) 84
Papillary thyroid cancer Unreached 11 ,0.001 0.027 0.001–0.68 0.029
Non papillary thyroid cancer Unreached 93
Any decrease tumor size3 49.8 36 0.006 0.32 0.13–0.75 0.009
Any increase tumor size 10 (6.2–13.8) 44
1Royal Marsden Hospital (RMH) 13 prognostic score is determined as follows: 0 points, normal lactate dehydrogenase (LDH), albumin $3.5 g/dL, a #2 metastatic sites;
1 point- LDH.upper limit of normal, albumin ,3.5 g/dL,.2 metastatic sites. Patients with 0–1 points had a good RMH score, and patients with 2–3 points had a poor
RMH score.
2Among the 149 patients with wtBRAF, 22 patients were treated with RAF/MEK targeting agents, 64 patients were treated with non RAF/MEK targeting agents, 18
patients never been enrolled in phase 1 trial after referral and 45 patients from melanoma department who were not referred to the phase 1 department the time of
the analysis.
3Patients who never had a restaging at the last follow-up or who never started on a phase 1 trial were excluded in the univariate analysis (N = 24).
4Only patients who were referred to the phase 1 clinic were considered in this analysis (Overall survival from time of referral to the phase 1 clinic).
doi:10.1371/journal.pone.0025806.t005
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Figure 5. Forest plot summarizing the clinical factors affecting overall survival after referral and displaying their hazard ratio and
95% Confidence interval calculated by Cox proportional hazards regression model in patients with wtBRAF advanced cancer.
doi:10.1371/journal.pone.0025806.g005
Figure 6. Kaplan Meier estimate of overall survival from time of diagnosis comparing patients with melanoma with V600K BRAF
mutation vs. other BRAF mutations. Tic marks represent patients who were alive and censored at time of last follow up. (One patient for whom
the time of diagnosis was unknown was excluded.)
doi:10.1371/journal.pone.0025806.g006
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individual studies with molecules including but not limited to
PLX4032, GSK2118436 (BRAF inhibitor), and GSK 1120212
(MEK1/2 inhibitor) in mutBRAF cancer [3–6]. Multivariate
analysis conducted on patients with wtBRAF found no association
between treatment with RAF/MEK targeting agents and survival.
Interestingly, we identified V600K BRAF mutation as a
prognostic factor associated with more aggressive behavior in
metastatic melanoma. Indeed, V600K associated with more brain
metastases, shorter time for both disease-free survival and OS from
diagnosis, and a trend towards a shorter OS following metastases
in comparison to melanoma with other types of mutBRAF
(Figure 6). Because of the small number of patients, it is unclear
as to how this would impact BRAF- targeted therapies, other than
the fact that treatment that penetrates the brain might be needed.
Our analysis has limitations: (i) the small number of patients in
each histologic group; (ii) the absence of randomization in regard
to the PFS and overall survival data; (iii)the possibility of selection
bias based on treatment choice; (iv) selection bias because we only
analyzed patients with metastatic disease and cannot therefore
ascertain the behavior of patients whose disease never metasta-
sized; (v) the retrospective nature of the study; and (vi) the fact that
multiple tests were analyzed for significance. Taken together, this
study must therefore be considered exploratory. Even so, several
observations that merit further investigations emerge. First, some
clinical features appear to differ between histologies despite the
presence of BRAF mutation. For instance, patients with colorectal
cancer and BRAF mutation showed a trend towards poor overall
survival from diagnosis while, in patients with melanoma, the
presence of a BRAF mutation was associated with a trend towards
better survival. Other factors, including a higher frequency of
women and younger patients with cancer harboring BRAF
mutation compared to those without the mutation, as well as a
lower likelihood to metastasize to the soft tissue, retroperitoneum
and lungs was seen across histologic groups, albeit not always in a
statistically significant manner. Overall, the only independent
factors predicting survival in BRAF- mutant patients in our clinic
was treatment with any RAF/MEK axis targeting agent and any
initial tumor regression. Of interest, our preliminary data also
suggest that the site of mutation may be important, since the
subgroup with V600K BRAF mutation (as opposed to V600E) was
associated with more brain metastases, and shorter time for both
disease-free and overall survival from diagnosis in melanoma.
These data support a role for BRAF as a driver mutation that
influences phenotype and that provides a druggable target for
patients with cancer.
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